ClinicalTrials.gg
CompletedNCT01967225Updated Oct 4, 2018Results posted

Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections

A Phase 3 interventional study of Tedizolid Phosphate (Sivextro, BAY1192631) and Linezolid in Skin Diseases, Infectious, sponsored by Bayer. Completed at 46 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-04.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
125
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this study is to see the efficacy and safety of BAY1192631 in Japanese patients with methicillin-resistant staphylococcus aureus (MRSA) (skin and soft tissue infections (SSTI) and SSTI-related bacteremia).

02

Conditions studied

  • Skin Diseases, Infectious

Keywords

  • Methicillin Resistant Staphylococcus Aureus,
  • Skin and soft tissue infection,
  • Bacteremia,
  • Tedizolid
03

In context

Skin Diseases, Infectious

45 studies on the registry are indexed under Skin Diseases, Infectious; 2 are open to participants now.

This study's enrollment of 125 is below the median of 161 across 37 interventional studies indexed under Skin Diseases, Infectious.

Browse Skin Diseases, Infectious studies →

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Suspected or confirmed Methicillin-resistant Staphylococcus aureus (MRSA) infection
  • Japanese Male and female patients aged 18 years or above
  • Diagnosis of Skin and soft tissue infection with MRSA either suspected or confirmed as the major cause of infection, with/without SSTI (skin and soft tissue infection)-derived MRSA bacteremia suspected

Exclusion criteria

Exclusion Criteria:

  • Having received any systemic antibacterial potentially effective against MRSA for >/=24 hours within 3 days prior to the first infusion of a study drug, or having received/expected to receive the medication within 24 hours prior to the first infusion, unless antibacterial therapy for >/=72 hours proves to be ineffective on or lack appropriate potency (resistant) to MRSA.
  • Moribund clinical condition such as death likely within the first 3 days of a study drug treatment
  • History of significant allergy or intolerance to linezolid or BAY1192631
  • Known or suspected (HIV) infection with a \< 200/μL
  • Chronic treatment with drugs
  • Active tuberculosis or non-tuberculous mycobacteriosis which need medical treatments
  • Current or anticipated neutropenia with \< 1,000/ mm\^3
  • (ALT) or Aspartate aminotransferase (AST) >/= 8 times the upper limit of reference range OR moderate to severe hepatic disease with score >/=10.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
125 participants (actual)

Study arms

  • Experimental
    Tedizolid Phosphate (Sivextro, BAY1192631)

    Participants received 200 mg BAY1192631 solution or tablet once daily (intravenous (I.V.) or oral (PO))

    Drug: Tedizolid Phosphate (Sivextro, BAY1192631)

  • Active comparator
    Linezolid

    Participants received 600 mg Linezolid solution or tablet twice daily, every 12 ± 3 hours (intravenous (I.V.) or oral (PO))

    Drug: Linezolid

Interventions

  • BAY1192631 solution or tablet 200 mg, once daily, Intravenous (IV) or By Mouth (PO) for 7-14 days for skin and soft tissue infections (SSTI) or 7-21 days for bacteremia.

  • Linezolid solution or tablet 600 mg, twice daily, every 12 ±3 hours, Intravenous (IV) or By mouth (PO) 7-14 days for skin and soft tissue infections (SSTI) or 7-21 days for bacteremia.

06

What researchers measure

Primary outcomes

  1. Clinical Response at Test of Cure (TOC)

    Clinical response was evaluated by the masked investigator as clinical cure, clinical failure and indeterminate on the basis of the clinical symptoms/findings, vital sign and laboratory data from screening period to each evaluation point. Measurements for the assessment of clinical response included body temperature, pulse/heart rate, respiration rate, and white blood cell or band cell count.

    Time frame: 7-14 days after the end of treatment (EOT) for skin and soft tissue infections (SSTI) and 4-6 weeks after EOT for bacteremia

  2. Microbiological Response at Test of Cure (TOC)

    Microbiological response was assessed in accordance with the Guidance for the method of microbiological assessment by Japanese Chemotherapy Society.

    Time frame: 7-14 days after the end of treatment (EOT) for skin and soft tissue infections (SSTI) and 4-6 weeks after EOT for bacteremia

Secondary outcomes

  1. Clinical Response at End of Treatment Visit (EOT)

    Clinical response was evaluated by the masked investigator as effective, ineffective and indeterminate on the basis of the clinical symptoms/findings, vital sign and laboratory data from screening period to each evaluation point. Measurements for the assessment of clinical response included body temperature, pulse/heart rate, respiration rate, and white blood cell or band cell count.

    Time frame: 7-14 days for skin and soft tissue infections (SSTI) or 7-21 days for bacteremia from the study drug administration

  2. Microbiological Response at End of Treatment (EOT)

    Microbiological response was assessed in accordance with the Guidance for the method of microbiological assessment by Japanese Chemotherapy Society.

    Time frame: 7-14 days for skin and soft tissue infections (SSTI) or 7-21 days for bacteremia from the study drug administration

  3. Change of the Lesion Size From the Screening Visit by Visit (Only Skin and Soft Tissue Infection [SSTI])

    Lesion size was measured by the masked investigators of erythema, edema, or induration whichever is largest.

    Time frame: Multiple time points up to 7-14 days after the end of treatment

  4. Reduction Ratio of the Lesion Size From the Screening Visit to Day 3 to Day 4 Visit (Only Skin and Soft Tissue Infection [SSTI])

    Lesion size was measured by the masked investigators of erythema, edema, or induration whichever is largest. Reduction ratio (%) = 100 \* (the post baseline value - baseline value) / baseline value. Negative values represent reduction of lesion size compared to baseline.

    Time frame: Baseline and Day 3/4, Day 5/13, EOT, TOC

07

Results

Posted Oct 4, 2018

Participant flow

The study was conducted in 46 study centers in Japan from 23 November 2013 (first subject, first visit) to 28 October 2016 (last subject, last visit).

Participant flow — Overall Study
MilestoneTedizolid Phosphate (Sivextro, BAY1192631)Linezolid
Started8441
Participants received treatment8341
Completed7238
Not completed123
Withdrew: Adverse event31
Withdrew: Withdrawal by subject21
Withdrew: Lack of efficacy11
Withdrew: Switching to other therapy20
Withdrew: Protocol driven decision point10
Withdrew: Logistical difficulties10
Withdrew: Protocol violation20

Outcome measures

PrimaryClinical Response at Test of Cure (TOC)

Clinical response was evaluated by the masked investigator as clinical cure, clinical failure and indeterminate on the basis of the clinical symptoms/findings, vital sign and laboratory data from screening period to each evaluation point. Measurements for the assessment of clinical response included body temperature, pulse/heart rate, respiration rate, and white blood cell or band cell count.

Time frame:
7-14 days after the end of treatment (EOT) for skin and soft tissue infections (SSTI) and 4-6 weeks after EOT for bacteremia
Reported as:
Number · Percentage of participants
Clinical Response at Test of Cure (TOC)
Percentage of participantsTedizolid Phosphate (Sivextro, BAY1192631) - SSTILinezoid - SSTITedizolid Phosphate (Sivextro, BAY1192631) - BacteremiaLinezoid - Bacteremia
Clinical cure86.2 (75.7 to 99.1)80.0—0.0
Clinical failure6.910.0—0.0
Indeterminate6.910.0—100.0
PrimaryMicrobiological Response at Test of Cure (TOC)

Microbiological response was assessed in accordance with the Guidance for the method of microbiological assessment by Japanese Chemotherapy Society.

Time frame:
7-14 days after the end of treatment (EOT) for skin and soft tissue infections (SSTI) and 4-6 weeks after EOT for bacteremia
Reported as:
Number · Percentage of participants
Microbiological Response at Test of Cure (TOC)
Percentage of participantsTedizolid Phosphate (Sivextro, BAY1192631) - SSTILinezoid - SSTITedizolid Phosphate (Sivextro, BAY1192631) - BacteremiaLinezoid - Bacteremia
Eradication93.190.0—100.0
Persistence3.40.0—0.0
Elimination(indeterminate)0.00.0—0.0
Missing3.410.0—0.0
SecondaryClinical Response at End of Treatment Visit (EOT)

Clinical response was evaluated by the masked investigator as effective, ineffective and indeterminate on the basis of the clinical symptoms/findings, vital sign and laboratory data from screening period to each evaluation point. Measurements for the assessment of clinical response included body temperature, pulse/heart rate, respiration rate, and white blood cell or band cell count.

Time frame:
7-14 days for skin and soft tissue infections (SSTI) or 7-21 days for bacteremia from the study drug administration
Reported as:
Number · Percentage of participants
Clinical Response at End of Treatment Visit (EOT)
Percentage of participantsTedizolid Phosphate (Sivextro, BAY1192631) - SSTILinezoid - SSTITedizolid Phosphate (Sivextro, BAY1192631) - BacteremiaLinezoid - Bacteremia
Effective93.190.0—50.0
Ineffective6.910.0—0.0
Indeterminate0.00.0—50.0
SecondaryMicrobiological Response at End of Treatment (EOT)

Microbiological response was assessed in accordance with the Guidance for the method of microbiological assessment by Japanese Chemotherapy Society.

Time frame:
7-14 days for skin and soft tissue infections (SSTI) or 7-21 days for bacteremia from the study drug administration
Reported as:
Number · Percentage of participants
Microbiological Response at End of Treatment (EOT)
Percentage of participantsTedizolid Phosphate (Sivextro, BAY1192631) - SSTILinezoid - SSTITedizolid Phosphate (Sivextro, BAY1192631) - BacteremiaLinezoid - Bacteremia
Eradication93.1100.0—100.0
Persistence6.90.0—0.0
Elimination (indeterminate)0.00.0—0.0
SecondaryChange of the Lesion Size From the Screening Visit by Visit (Only Skin and Soft Tissue Infection [SSTI])

Lesion size was measured by the masked investigators of erythema, edema, or induration whichever is largest.

Time frame:
Multiple time points up to 7-14 days after the end of treatment
Reported as:
Mean · cm^2
Change of the Lesion Size From the Screening Visit by Visit (Only Skin and Soft Tissue Infection [SSTI])
cm^2Tedizolid Phosphate (Sivextro, BAY1192631) - SSTILinezoid - SSTI
Day 3/4-62.05 ± 96.89-173.93 ± 210.19
Day 5 to 13-134.31 ± 153.3-317.66 ± 410.86
End of treatment-174.96 ± 283.05-280.69 ± 386.64
Test of cure (n=28, 9)-212.63 ± 369.43-314.18 ± 402.93
SecondaryReduction Ratio of the Lesion Size From the Screening Visit to Day 3 to Day 4 Visit (Only Skin and Soft Tissue Infection [SSTI])

Lesion size was measured by the masked investigators of erythema, edema, or induration whichever is largest. Reduction ratio (%) = 100 \* (the post baseline value - baseline value) / baseline value. Negative values represent reduction of lesion size compared to baseline.

Time frame:
Baseline and Day 3/4, Day 5/13, EOT, TOC
Reported as:
Mean · Percentage
Reduction Ratio of the Lesion Size From the Screening Visit to Day 3 to Day 4 Visit (Only Skin and Soft Tissue Infection [SSTI])
PercentageTedizolid Phosphate (Sivextro, BAY1192631) - SSTILinezoid - SSTI
Day3/4-32.32 ± 40.50-61.46 ± 33.31
Day 5 to 13-53.30 ± 41.66-94.61 ± 6.32
End of Treatment-67.69 ± 32.40-90.09 ± 26.38
Test of Cure-81.82 ± 23.99-99.09 ± 2.08

Adverse events

Collected over 25 days after the last study medication administration. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tedizolid Phosphate (Sivextro, BAY1192631)—7/83 (8.4%)64/83 (77.1%)
Linezolid—4/41 (9.8%)31/41 (75.6%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventTedizolid Phosphate (Sivextro, BAY1192631)Linezolid
CellulitisInfections and infestations1/832/41
Bone marrow failureBlood and lymphatic system disorders0/831/41
SepsisInfections and infestations0/831/41
Anal abscessInfections and infestations0/831/41
Muscle abscessInfections and infestations0/831/41
OsteomyelitisInfections and infestations2/830/41
Gas gangreneInfections and infestations1/830/41
Necrotising fasciitisInfections and infestations1/830/41
PneumoniaInfections and infestations1/830/41
SternitisInfections and infestations1/830/41
Most frequent other events
Showing 10 of 133
Most frequent other events
EventTedizolid Phosphate (Sivextro, BAY1192631)Linezolid
Dermatitis contactSkin and subcutaneous tissue disorders5/836/41
ConstipationGastrointestinal disorders4/834/41
DiarrhoeaGastrointestinal disorders4/834/41
NauseaGastrointestinal disorders5/834/41
VomitingGastrointestinal disorders4/834/41
Injection site painGeneral disorders5/834/41
Hepatic function abnormalHepatobiliary disorders3/833/41
Alanine aminotransferase increasedInvestigations5/832/41
AnaemiaBlood and lymphatic system disorders1/832/41
ThrombocytopeniaBlood and lymphatic system disorders0/832/41

Baseline characteristics

Participants who received treatment are analyzed for baseline characteristics.

Age, Customized
Age, Customized(Participants)Tedizolid Phosphate (Sivextro, BAY1192631) - SSTILinezoid - SSTITedizolid Phosphate (Sivextro, BAY1192631) - BacteremiaLinezoid - BacteremiaTotal
< 65 years31203054
65 - 75 years3191243
> 75 years17100027
Sex: Female, Male
Sex: Female, Male(Participants)Tedizolid Phosphate (Sivextro, BAY1192631) - SSTILinezoid - SSTITedizolid Phosphate (Sivextro, BAY1192631) - BacteremiaLinezoid - BacteremiaTotal
Female27122142
Male52272182
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Tedizolid Phosphate (Sivextro, BAY1192631) - SSTILinezoid - SSTITedizolid Phosphate (Sivextro, BAY1192631) - BacteremiaLinezoid - BacteremiaTotal
Mean25.52 ± 4.7025.72 ± 5.8030.75 ± 11.1922.35 ± 0.6425.70 ± 5.34
Lesion area
Lesion area(Participants)Tedizolid Phosphate (Sivextro, BAY1192631) - SSTILinezoid - SSTITedizolid Phosphate (Sivextro, BAY1192631) - BacteremiaLinezoid - BacteremiaTotal
<=75 cm^22514——39
>75 cm^25425——79
Primary diagnosis
Primary diagnosis(Participants)Tedizolid Phosphate (Sivextro, BAY1192631) - SSTILinezoid - SSTITedizolid Phosphate (Sivextro, BAY1192631) - BacteremiaLinezoid - BacteremiaTotal
Deep SSTI44220066
Chronic pyoderma32005
Infection secondary to wound, burn, surgical wound15100025
Infection secondary to ulcer1750022
Bacteremia00426
08

Study locations

46 sites
  • Nagakute, Aichi 480-1195, Japan
  • Nagoya, Aichi 455-8530, Japan
  • Nagoya, Aichi 457-8510, Japan
  • Toyoake, Aichi 470-1192, Japan
  • Yoshida, Fukui 910-1193, Japan
  • Kasuga, Fukuoka 816-0864, Japan
  • Kitakyushu, Fukuoka 802-0077, Japan
  • Miyako-gun, Fukuoka 800-0344, Japan
  • Sapporo, Hokkaido 006-8555, Japan
  • Sapporo, Hokkaido 060-0061, Japan
  • Amagasaki, Hyogo 660-8511, Japan
  • Kobe, Hyogo 650-0017, Japan
  • Inashiki-gun, Ibaraki 300-0395, Japan
  • Tsukuba, Ibaraki 305-8576, Japan
  • Kamakura, Kanagawa 247-8533, Japan
  • Sagamihara, Kanagawa 252-0375, Japan
  • Yokohama, Kanagawa 231-8682, Japan
  • Koshi, Kumamoto 861-1196, Japan
  • Tsu, Mie 514-1101, Japan
  • Sendai, Miyagi 983-8520, Japan
  • Nakagami-gun, Okinawa 901-2393, Japan
  • Shimajiri, Okinawa 901-0493, Japan
  • Hamamatsu, Shizuoka 430-0929, Japan
  • Iwata, Shizuoka 438-8550, Japan
  • Numazu, Shizuoka 410-8555, Japan
  • Meguro-ku, Tokyo 152-8902, Japan
  • Musashimurayama, Tokyo 208-0011, Japan
  • Ota-ku, Tokyo 143-0013, Japan
  • Ota-ku, Tokyo 143-8541, Japan
  • Ota-ku, Tokyo 145-0065, Japan
  • Setagaya-ku, Tokyo 158-8531, Japan
  • Shinagawa, Tokyo 141-8625, Japan
  • Shinjuku-ku, Tokyo 162-8655, Japan
  • Tachikawa, Tokyo 190-0014, Japan
  • Yonago, Tottori 683-8605, Japan
  • Shimonoseki, Yamaguchi 750-8520, Japan
  • Kofu, Yamanashi 400-8506, Japan
  • Fukuoka, 810-0001, Japan
  • Gifu, 500-8513, Japan
  • Kochi, 781-8555, Japan
  • Kumamoto, 860-0008, Japan
  • Nagasaki, 852-8501, Japan
  • Osaka, 534-0021, Japan
  • Shizuoka, 420-8527, Japan
  • Shizuoka, 424-8636, Japan
  • Toyama, 930-0194, Japan
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2013 to primary completion in Oct 2016, 35 months.

Results were first posted in Oct 2018, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2013
First posted
Oct 22, 2013
StartActual
Nov 23, 2013
Primary completionActual
Oct 28, 2016
CompletionActual
Oct 28, 2016
Results first posted
Oct 4, 2018
Last update
Oct 4, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01967225
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Oct 22, 2013
Start date
Nov 23, 2013
Primary completion
Oct 28, 2016
Completion
Oct 28, 2016
Results posted
Oct 4, 2018
Last update
Oct 4, 2018

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tedizolid phosphate

Start the discussion